Druggable Molecular Pathways in Chronic Lymphocytic Leukemia

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Chronic lymphocytic leukemia (CLL) exhibits significant clinical heterogeneity due to molecular complexity.
• Key affected pathways in CLL include B-cell receptor (BCR) signaling, apoptosis, NF-κB, and NOTCH1 signaling.

Purpose of the Study:

• To review druggable pathways in CLL.
• To explain the biological basis for the efficacy of targeted therapies in CLL.

Main Methods:

• Literature review of targeted therapies and signaling pathways in CLL.
• Analysis of clinical trial data for targeted agents.

Main Results:

• Targeted inhibitors of Bruton tyrosine kinase (BTK), phosphoinositide 3-kinase (PI3K), and BCL2 have revolutionized CLL therapy.
• BCL2 inhibitors like venetoclax show significant activity in a fixed-duration regimen.
• Targeted agents overcome chemoresistance in high-risk CLL with TP53 disruption.

Conclusions:

• Targeted therapies exploiting BCR signaling and apoptosis pathways are highly effective in CLL.
• NOTCH and NF-kB signaling pathways represent future therapeutic targets and biomarkers for precision medicine in CLL.